Trial Profile
Single-center, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of a Single Dose of 40 mg ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2014
Price :
$35
*
At a glance
- Drugs Ponesimod (Primary)
- Indications Graft-versus-host disease; Multiple sclerosis; Plaque psoriasis
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 26 Aug 2014 New trial record